Cheng Liu - Estrella Immunopharma President CEO
| ESLAW Stock | 0.09 0 3.53% |
CEO
Cheng Liu is President CEO of Estrella Immunopharma
| Age | 57 |
| Address | 5858 Horton Street, EmeryVille, CA, United States, 94608 |
| Phone | 510 318 9098 |
| Web | https://www.estrellabio.com |
Estrella Immunopharma Management Efficiency
The company has return on total asset (ROA) of (1.7475) % which means that it has lost $1.7475 on every $100 spent on assets. This is way below average. Estrella Immunopharma's management efficiency ratios could be used to measure how well Estrella Immunopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.1 in 2024. Return On Capital Employed is likely to climb to -0.18 in 2024. At this time, Estrella Immunopharma's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 302.3 K in 2024, whereas Non Current Assets Total are likely to drop 0.00 in 2024.Similar Executives
| Found 4 records | CEO Age | ||
| Joseph MBA | Milestone Pharmaceuticals | 56 | |
| John Tucker | Scpharmaceuticals | 61 | |
| Eric MBA | Seres Therapeutics | 48 | |
| BAO BCh | Eliem Therapeutics | 48 | |
Management Performance
| Return On Asset | -1.75 |
Estrella Immunopharma Leadership Team
Elected by the shareholders, the Estrella Immunopharma's board of directors comprises two types of representatives: Estrella Immunopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Estrella. The board's role is to monitor Estrella Immunopharma's management team and ensure that shareholders' interests are well served. Estrella Immunopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Estrella Immunopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cheng Liu, President CEO | ||
| Jiandong Xu, Chief Officer |
Estrella Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Estrella Immunopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.75 | ||||
| Number Of Shares Shorted | 21.94 K | ||||
| EBITDA | (7.31 M) | ||||
| Net Income | (7.31 M) | ||||
| Total Debt | 180.7 K | ||||
| Book Value Per Share | (2.89) X | ||||
| Cash Flow From Operations | (16.07 M) | ||||
| Beta | -0.09 | ||||
| Total Asset | 4.45 M | ||||
| Retained Earnings | (19.5 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Estrella Stock Analysis
When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.